AXLRx Book a callCommission

Big Pharma · Pulmonology

Sanofi — Pulmonology

Sanofi across Pulmonology: the full competitive set, and the 1 AXLRx report mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

Commission a Sanofi report

By therapy area

Therapy area All areas ImmunologyRare DiseasePulmonology

Market All United States

AXLRx reports featuring Sanofi — Pulmonology

CI · Pulmonology · CI Team · Launch Lead US COPD Competitive Intelligence Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier. US · In-Market · Read report →